The University of Oxford believes to prove itself in making a mark through their search for COVID-19 vaccine after the team of researchers discovered that the discovery could provide a “double protection” against the deadly coronavirus following human trials as said by the media reports in UK.
According to a senior source of
the trial, some blood samples taken from a group of UK volunteers given a dose of the vaccine showed that it stimulated the body to produce antibodies and killer T-cells. Studies show that antibodies might fade away within a small time but the T-cells will stay in circulation for years. Although the results till date are quite promising as well as positive yet it does not confirm that the Oxford vaccine provides long-lasting immunity against the virus.
The antibodies and the T-cells are considered to be a “double defense” against COVID-19. “The Lancet” medical journal confirms that it will publish an early-stage human trial data from the Oxford team on Monday. The final dates are not released yet and it seems that putting up a certain date is not right as things might go wrong; however, they speak of the reality being that by working with a big pharma company, the vaccine would probably be available around September and that is possibly the known target that the team is working up on.
The pharmaceutical company said that the phase 1 trials are due to finish and that a phase 3 trial has begun which will see the vaccine given to thousands of people so as to test its efficacy and safety. The vaccine is named as “ChAdOx1 nCoV-19” and is based on a weak version of the common cold that causes infections in chimpanzees. It further contains the genetic material of the spike protein of SARS-CoV-2.